Mundipharma – Monday Breakfast 7:30 – 8:30am, The complexities, comorbidities and consequences of pharmaceutical opioids: An overview of the Australian situation and early findings of post-marketing surveillance of a potentially abuse-deterrent formulation of oxycodone.
There has been a considerable increase in the long-term prescribing of opioids for chronic non-cancer pain (CNCP) in a number of countries, including but not limited to the United States, Canada and Australia, which has caused concern in the community and among health professionals about the misuse of pharmaceutical opioids, and their potential for harm.
Professor Louisa Degenhardt will discuss these issues, and talk about problematic opioid use and its related harms including injection, use and dependence, and overdose.
Nevro – Monday Breakfast 7:30 – 8:30am, Advances in Spinal Cord Stimulation: (HF10 Technology and Latest Results from Randomized Clinical Trial)
HF10, is a major advance in neuromodulation for chronic pain. A large, randomized clinical trial (RCT) has been conducted in the United States to evaluate this advanced technology. The landmark study provides the first Level 1 evidence for SCS for chronic back pain.
Dr. Leo Kapural and Dr. Kasra Amirdelfan, leading experts on neuromodulation and investigators of this study, will be presenting. This session will inform the audience of an advanced SCS technology and the first Level 1 evidence for SCS for back pain, which have important applicability to physicians for treating patients with few options.
Indivior Afternoon Session – Monday 5:30 – 6:30pm, The abuse, misuse and dependence of prescription opioids – issues and challenges
This session will briefly outline the increasing issue of prescription opioid drug abuse, and the challenge of identifying patients who lose control of their medication and, subsequently develop an opioid substance use disorder. The focus will be on identification of problematic prescription use, the challenges in raising the issue with patients, and discussion of available treatment options including Medication Assisted Treatment.
BioCSL – Tuesday Breakfast 7.30 – 8.30 am, Pain intensity vs. functional improvement…time to shift our thinking
This clinically orientated symposium challenges the place of ‘pain intensity’ as the primary measure of analgesic efficacy when treating chronic pain patients. Improving function is a shared treatment goal of multidisciplinary pain management plans with pharmacological based analgesia playing an important role in achieving this goal. Therefore this symposium will question if we should be measuring the analgesia of drugs based on quality of life improvements such as function instead of pain relief?
Pfizer – Tuesday Breakfast 7.30 – 8.30 am, Putting neuropathic pain guidelines into practice
In the IASP year against neuropathic pain, join Professor Stephan Schug as he discusses the diagnostic protocols and evidence based treatment for neuropathic pain with Professor Rainer Freynhagen via weblink from Germany.
Reckitt Benckiser – Health, Home and Hygiene – Wednesday Breakfast 7:30 – 8:30am, Is codeine a fait accompli for patients needing more pain relief?
For many patients (and prescribers) codeine-combination analgesics may be the next step in pain relief, that they are unable to avoid, when they need more pain relief. Codeine combinations have a established history of use however they also have well documented challenges. In this session Dr Kubler will review the clinical data for NEW Nuromol® with Synchrotech™ a fixed dose combination of Ibuprofen (200mg) and Paracetamol (500mg).
Orthocell – Wednesday Breakfast 7:30 – 8:30am, Management of Tendinopathy
Tendinopathy is a common cause of pain in patients ranging from the weekend warrior through to the elite athlete. There are many conservative treatments available at present but outcomes remain unsatisfactory. This session will focus on discussions regarding pathobiology of tendinopathy and address various biological treatment options for tendinopathy. Clinical evidence of autologous tenocytes injections for tendinopathy will be presented at this session.